Pharmaceutical Services Section, Nippon Medical School, Chiba Hokusoh Hospital, 1715 Kamagari, Chiba, 270-1694, Japan.
J Pharm Pharm Sci. 2010;13(2):254-62. doi: 10.18433/j3hg6q.
The purpose of our study was to optimize lipid-lowering therapy in patients undergoing coronary revascularization and to determine whether the percentage change in low-density lipoprotein-cholesterol (LDL-C) level in the 3 months after coronary revascularization could be used as a predictor of the time to recurrence of coronary artery disease (CAD).
Biochemical values of patients undergoing lipid-lowering therapy after receiving coronary revascularization at the Nippon Medical School Chiba Hokusoh Hospital, Japan, were retrospectively investigated. Recurrence of a cardiovascular event (CVE) was defined by death, myocardial infarction, or angina caused by coronary revascularization more than 3 months after the first event.
Of 171 patients under secondary preventive care who had at least one recurrence of a CVE, 75 showed evidence of objective stenotic lesions on coronary angiography. Among these 75 patients, exclusion of those in whom coronary revascularization had not been performed at disease onset, balloon dilatation had been used, serum lipid levels had not been measured, or coronary revascularization had been applied to restenosis left 44 patients suitable for inclusion in the study group. Although the mean value of high density lipoprotein-cholesterol did not change in the 3 months after coronary revascularization, that of (LDL-C) significantly decreased. A significant positive correlation was identified between % decrease in LDL-C and number of days to CVE recurrence. The average LDL-C value (102.8+/-21.7 mg/dL) in the group of patients with no recurrence within 5 years was significantly lower than that (135.3+/-46.1 mg/dL) in the recurrence group (P = 0.0088). The % of patients achieving the LDL-C target level (non-recurrence group vs. recurrence group: 50.0% vs. 16.7%; P = 0.032) and the % decrease in LDL-C (31.0%+/-12.6% vs. 9.6+/-21.0%, P = 0.0012) were significantly greater in the non-recurrence group than in the recurrence group.
From our present study, a decrease in LDL-C 3 months after revascularization surgery reduces the rate of CVE relapse. The % LDL-C decrease could serve as a useful predictor of CVE recurrence, in addition to LDL-C values and achievement of the LDL-C target level.
本研究旨在优化接受冠状动脉血运重建的患者的降脂治疗,并确定冠状动脉血运重建后 3 个月时低密度脂蛋白胆固醇(LDL-C)水平的变化百分比是否可用作冠心病(CAD)复发时间的预测指标。
回顾性调查了在日本顺天堂大学千叶北总合医院接受冠状动脉血运重建后接受降脂治疗的患者的生化值。心血管事件(CVE)的复发定义为首次事件后 3 个月以上因死亡、心肌梗死或冠状动脉血运重建引起的心绞痛。
在 171 名接受二级预防护理且至少有一次 CVE 复发的患者中,75 名患者的冠状动脉造影显示存在客观狭窄病变。在这 75 名患者中,排除了那些在发病时未进行冠状动脉血运重建、使用了球囊扩张术、未测量血脂水平或对再狭窄进行了冠状动脉血运重建的患者,留下了 44 名适合纳入研究组的患者。尽管冠状动脉血运重建后 3 个月高密度脂蛋白胆固醇的平均值没有变化,但 LDL-C 的平均值显著降低。LDL-C 降低的百分比与 CVE 复发的天数之间存在显著的正相关关系。5 年内无复发组患者的平均 LDL-C 值(102.8+/-21.7 mg/dL)明显低于复发组(135.3+/-46.1 mg/dL)(P=0.0088)。达到 LDL-C 目标水平的患者比例(无复发组 vs. 复发组:50.0% vs. 16.7%;P=0.032)和 LDL-C 降低百分比(31.0%+/-12.6% vs. 9.6+/-21.0%,P=0.0012)在无复发组均显著高于复发组。
从我们目前的研究来看,血管重建术后 3 个月 LDL-C 的降低可降低 CVE 复发率。LDL-C 降低百分比除 LDL-C 值和达到 LDL-C 目标水平外,还可作为 CVE 复发的有用预测指标。